Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc.
Four Tower Bridge
Suite 200 200 Barr Harbor Drive
West Conshohocken, PA 19428
United States
267 824 2827
https://www.madrigalpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 376
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 939.83k | N/A | 1952 |
| Mr. Brian J. Lynch J.D. | Senior VP & General Counsel | 763.75k | 1.27M | 1962 |
| Mr. Alex G. Howarth | Executive Officer | 757.26k | N/A | 1969 |
| Mr. William J. Sibold | CEO, President & Director | N/A | N/A | 1966 |
| Ms. Mardi C. Dier | CFO, Principal Financial Officer, Principal Accounting Officer & Senior VP | N/A | N/A | 1964 |
| Mr. Ronald Filippo | Chief Information Officer | N/A | N/A | N/A |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | N/A | N/A | N/A |
| Dr. Kianoush Motesharei Ph.d. | Senior Vice President of Business & Corporate Development | N/A | N/A | 1970 |
| Mr. Clint Wallace | Chief Human Resources Officer | N/A | N/A | N/A |
| Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | N/A | N/A | N/A |
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Corporate Governance
Madrigal Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 7.
